A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
NCT ID: NCT00118755
Last Updated: 2011-03-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
435 participants
INTERVENTIONAL
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT00642603
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
NCT00069095
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
NCT01135498
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
NCT01077739
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
NCT00484939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
capecitabine
850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
Oxaliplatin
130 mg/m\^2 IV on Day 1 of each 3-week cycle
bevacizumab
7.5 mg/kg IV on Day 1 of each 3-week cycle
2
capecitabine
1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
Oxaliplatin
85 mg/m\^2 IV on Day 1 of each 2-week cycle
bevacizumab
5 mg/kg IV on Day 1 of each 2-week cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
capecitabine
850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
Oxaliplatin
130 mg/m\^2 IV on Day 1 of each 3-week cycle
bevacizumab
7.5 mg/kg IV on Day 1 of each 3-week cycle
capecitabine
1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
Oxaliplatin
85 mg/m\^2 IV on Day 1 of each 2-week cycle
bevacizumab
5 mg/kg IV on Day 1 of each 2-week cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>=1 measurable target lesion
Exclusion Criteria
* Previous treatment with bevacizumab
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hoffmann-La Roche
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML18491
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.